Table 1.
Demographic and clinical characteristics of Parkinson's disease patients stratified according to dopaminergic treatment response.
| Total | Weak responders | Strong responders | F (df) | p | |
|---|---|---|---|---|---|
| N | 30 | 15 | 15 | – | – |
| Age (years) | 65.37 ± 7.05 | 68.27 ± 7.56 | 62.47 ± 5.28 | 5.93 (28) | 0.021⁎ |
| Gender (male/female) | 17/13 | 8/7 | 9/6 | – | χ2 = 0.14, p = .71 |
| Education (years) | 14.1 ± 2.95 | 13.4 ± 2.82 | 14.8 ± 3 | 1.10 (27) | 0.34 |
| Disease duration (years) | 11.4 ± 3.43 | 10.87 ± 3.81 | 11.93 ± 3.03 | 0.78 (27) | 0.386 |
| Levodopa duration (years) | 8.529 ± 4.055 | 8.64 ± 4.2 | 8.42 ± 4.05 | 0.86 (27) | 0.363 |
| Levodopa equivalent dose (mg) | 1385.98 ± 664.75 | 1155.65 ± 680.28 | 1600.97 ± 582.85 | 1.84 (27) | 0.186 |
| UPDRS-III DT-off | 31.03 ± 10.31 | 28.27 ± 10.05 | 33.80 ± 10.13 | 1.48 (27) | 0.235 |
| UPDRS-III DT-on | 14.77 ± 7.58 | 17.20 ± 8.12 | 12.33 ± 6.37 | 1.73 (27) | 0.199 |
| UPDRS-III-change | 16.27 ± 7.06 | 11.07 ± 3.73 | 21.47 ± 5.59 | 23.93 (27) | <0.0001⁎⁎ |
| UPDRS-IV | 4.60 ± 3.65 | 3.33 ± 3.0 | 5.87 ± 3.871 | 2.61 (27) | 0.118 |
| NMSS total score | 15.10 ± 19.18 | 13.53 ± 20.79 | 16.67 ± 18.015 | 0.50 (27) | 0.485 |
| MoCA | 25.77 ± 2.34 | 25.53 ± 2.47 | 26.00 ± 2.27 | 0.073 (27) | 0.789 |
Note: Mean ± SD are shown.
Abbreviations: DT -on medicated state; DT-off unmedicated state; NMSS non-motor symptoms scale; MoCA Montreal Cognitive Assessment; UPDRS Unified Parkinson's Disease Rating Scale (-III motor symptoms; -IV motor complications).
⁎
Significant p-value from ANOVA analysis.
⁎⁎
Significant p-value from ANCOVA analysis controlling for age differences.